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Abstract
In order to explore the use of exchangeable poly(ethylene glycol) (PEG)-modified diacylphosphatidylethanolamines (PE)
to temporarily shield binding ligands attached to the surface of liposomes, a model reaction based on inhibition and
subsequent recovery of biotinylated liposome binding to streptavidin immobilized on superparamagnetic iron oxide particles
(SA magnetic particles) was developed. PEG-lipid incorporation into biotinylated liposomes decreased liposome binding to
SA magnetic particles in a non-linear fashion, where as little as 0.1 mol% PEG-PE resulted in a 20% decrease in binding.
Using an assay based on inhibition of binding, PEG2000-PE transfer from donor liposomes to biotinylated acceptor liposomes
could be measured. The influence of temperature and acyl chain composition on the transfer of PEG-diacyl PEs from donor
liposomes to acceptor liposomes, consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine, cholesterol and N-((6-biotinoyl)a-
mino)hexanoyl)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (54.9:45:0.1 mole ratio), was measured. Donor liposomes
were prepared using 1,2-distearoyl-sn-glycero-3-phosphocholine (50 mol%), cholesterol (45 mol%) and 5 mol% of either
PEG-derivatized 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE-PEG2000), 1,2-dipalmitoyl-sn-glycero-3-phos-
phoethanolamine (DPPE-PEG2000), or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG2000). Transfer of
DSPE-PEG2000 to the donor liposomes was not detected under the conditions employed. In contrast, DMPE-PEG2000
was transferred efficiently even at 4‡C. Using an acceptor to donor liposome ratio of 1:4, the time required for DMPE-
PEG2000 to become evenly distributed between the two liposome populations (TEQ) at 4‡C and 37‡C was approx. 2 and 6 0.5
h, respectively. An increase in acyl chain length from C14:0 to C16:0 of the PEG-lipid resulted in a significant reduction in
the rate of transfer as measured by this assay. The transfer of PEG-lipid out of biotinylated liposomes was also studied in
mice following intravenous administration. The relative rates of transfer for the various PEG-lipids were found to be
comparable under in vivo and in vitro conditions. These results suggest that it is possible to design targeted liposomes with
the targeting ligand protected while in the circulation through the use of PEG-lipids that are selected on the basis of exchange
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1. Introduction
Intermembrane transfer of conjugated lipids is of
interest due to the active roles such lipids play in
controlling surface reactions. Biologically relevant
exchange processes include membrane fusion [1]
and intracellular signaling mediated by the transfer
of glycosylphosphatidylinositol (GPI)-linked peptides
[2]. Lipid transfer is also becoming an important at-
tribute in the development of liposomes as biophar-
maceutical delivery systems. Two areas of particular
interest concern: (i) membrane dissociation of anti-
body/phospholipid conjugates following interaction
with a target ligand [3] and (ii) applications involving
controlled loss of poly(ethylene glycol) (PEG) lipids
to achieve a transformation of the liposome’s surface
characteristics [4,5]. It has been established that
PEG-modi¢ed lipids can transfer out of liposomal
membranes, a property that is dependent on the
acyl chain composition of the PEG-modi¢ed lipids
as well as the size of the PEG moiety [6]. Formula-
tions can be designed where PEG-lipid transfer is
associated with a change in the liposomal properties
and this is perhaps best illustrated by the transfor-
mation of a stable liposome to one that is highly
fusogenic [4,5,7].
The concept that PEG-lipid transfer could trans-
form the properties of a liposome is novel and many
practical applications of this technology can be con-
sidered. For example, despite the bene¢cial e¡ect of
PEG-lipid incorporation on liposome circulation life-
time [8^11], the development of liposomes with sur-
face-grafted PEG moieties and attached targeting li-
gands has been restricted because of PEG-mediated
inhibition of binding reactions between the targeting
ligand and its binding site [12,13]. In order to address
this problem, investigators have been coupling the
targeting ligand to the distal end of PEG moieties
which are chemically attached to lipids incorporated
in the liposomes [14^19]. The rationale for the latter
approach can be questioned given the propensity of
the resulting liposome to be immunogenic [20]. In
addition, the stability of the ligand-conjugated
PEG-lipid in the liposomal membrane is potentially
problematic given the tendency of PEG-lipids to ex-
change out of liposomes [6]. This problem may be
exacerbated with the additional forces that play a
role in dissociation/extraction of a lipid linked to
an antibody following antibody antigen interaction
[3]. An alternative approach to address this problem
is to employ PEG-modi¢ed lipids that can be trans-
ferred from the lipid bilayer thereby slowly exposing
small, surface-associated, targeting ligands.
In this regard, studies on lipid transfer are of par-
ticular interest in the development of liposomes with
surface-active groups, such as a targeting ligand or
charged moiety. Intervesicle transfer of phospholip-
ids has been well documented in the past [6,21^23].
Conjugation of hydrophilic macromolecules, includ-
ing PEG, to lipid anchors is known to a¡ect the rate
of transfer of the entire phospholipid out of the bi-
layer [6]. In this study, we describe a method to mea-
sure PEG-lipid transfer based on a functional assay
for quantifying liposomal PEG-lipid content in the
acceptor liposome. More speci¢cally, we utilized well
characterized biotin^streptavidin interactions as a
tool to study (i) PEG-lipid transfer as measured by
the generation of a surface shield that prevents bio-
tinylated liposome binding to streptavidin immobi-
lized on 1 Wm superparamagnetic iron oxide particles
and (ii) the e¡ect of PEG-grafted polymers on bio-
tinylated liposome binding to a de¢ned surface. The
assay described provides a very sensitive means to
assess PEG-lipid transfer. From the perspective of
using exchangeable PEG-modi¢ed lipids to shield
small targeting ligands on the surface of liposomes,
the results indicate that even small amounts
(6 1 mol%) of residual PEG-grafted lipids can
lead to signi¢cant reductions in speci¢c target bind-
ing.
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2. Materials and methods
2.1. Materials
Cholesterol (Chol) and streptavidin immobilized
on superparamagnetic iron oxide particles were pur-
chased from Sigma (St. Louis, MO). 1,2-Distearoyl-
sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-n-[methoxy(poly-
ethylene glycol)-2000] (DSPE-PEG2000), 1,2-dimyris-
toyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(-
polyethylene glycol)-2000] (DMPE-PEG2000), 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-n-[m-
ethoxy(polyethylene glycol)-2000] (DPPE-PEG2000),
1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine-
n-[methoxy(polyethylene glycol)-2000 (DOPE-
PEG2000) and 1,2-dioleoyl-sn-glycero-3-phosphocho-
line (DOPC) were purchased from Avanti Polar Lip-
ids (Birmingham, AL). N-((6-Biotinoyl)amino)hexa-
noyl)-1,2-distearoyl-sn-glycero-3-phosphoethanola-
mine (Bx-DSPE), 3H-DSPE-PEG2000, 3H-DPPE-
PEG2000, and 3H-DMPE-PEG2000 were purchased
from Northern Lipids (Vancouver, Canada). C14-
Cer-PEG2000 was a gift from Inex Pharmaceuticals
(Vancouver, Canada). Pico-Fluor 40 scintillation
cocktail was obtained from Canberra-Packard Can-
ada (Mississauga, ON). Nuclepore polycarbonate ¢l-
ters were obtained from Watman (Clifton, NJ). Bio-
gel A15M size exclusion gel was obtained from Bio-
Rad (Mississauga, ON). 3H-Cholesteryl hexadecyl
ether (CHE) was obtained from NEN Life Science
(Boston, MA). RAG-2 mice and Balb/c mice were
bred in-house at the BC Cancer Agency animal fa-
cility (Vancouver, Canada).
2.2. Preparation of large unilamellar vesicles
Liposomes were prepared using the extrusion
method of Mayer et al. [24]. Lipid mixtures (100^
150 Wmoles total lipid) were ¢rst dissolved in chloro-
form. 3H-Cholesteryl hexadecyl ether, used as a lipo-
some label, was added to the lipid mixture to obtain
a speci¢c activity of 0.1 WCi/Wmole. A lipid ¢lm was
formed from the lipid mixture by ¢rst drying under
nitrogen gas and then under high vacuum for at least
3 h. The lipid ¢lm was hydrated at 65‡C in 1.5 ml of
HEPES-bu¡ered saline (HBS; pH 7.4). The resulting
multilamellar vesicles were subjected to ¢ve freeze^
thaw cycles and then extrusion (10 times) using two
0.08 Wm and one 0.1 Wm polycarbonate membranes
with an extrusion device (Lipex Biomembranes, Van-
couver, Canada) which was thermoregulated at 65‡C.
Liposome size was determined by quasielastic light
scattering (QELS) using a Nicomp 370 submicron
particle sizer operating at a wavelength of 632.8
nm. The liposomes used in this study exhibited diam-
eters of 100^120 nm.
2.3. Biotinylated liposome binding assay
Biotinylated liposomes (DOPC/Chol/Bx-DSPE;
55:45:0.1) binding to target was determined by in-
cubating the liposomes (100 nmoles in 100 Wl HBS)
for 20 min at room temperature with 100 Wl of
streptavidin immobilized on iron oxide particles pre-
pared in a suspension provided by the manufacturer
(suspension in 0.85% NaCl, 0.01 M phosphate, pH
8.0, containing 0.1% bovine serum albumin, 15 mM
sodium azide). Unbound liposomes in the superna-
tant were removed from the mixture after separation
using a magnetic separator (Advanced Magnetics,
Cambridge, MA). SA magnetic particles with bound
liposomes were then collected after several washes
and the radioactivity was counted using 5 ml of
Pico-Fluor 40 and a Beckman LS 3801 scintillation
counter. The radioactivity counted was a direct mea-
sure of the amount of liposomal lipid bound to
streptavidin. The radioactivity of 3H-CHE associated
with SA magnetic particles was measured in the lipo-
somal PEG-lipid transfer assay and the radioactivity
of 14C-CHE was measured in the micellar PEG-lipid
transfer assay. The data obtained were averaged
from duplicates within the same experiment unless
otherwise stated.
2.4. PEG-lipid transfer experiments
Intervesicle transfer of PEG-lipids was determined
indirectly by measuring the inhibition of biotinylated
liposomes (acceptor liposomes) binding to streptavi-
din due to the incorporation of PEG-lipids in these
liposomes. DSPC/Chol liposomes containing 5 mol%
of either DSPE-PEG2000, DPPE-PEG2000, or DMPE-
PEG2000 were used as donor liposomes. In the trans-
fer assay, acceptor liposomes were incubated with
donor liposomes using conditions speci¢ed in each
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experiment. Subsequently, 100 Wl of SA magnetic
particles were added to the liposome mixture to mea-
sure biotinylated liposome binding to SA magnetic
particles as described above. PEG-lipid transferred to
biotinylated acceptor liposomes was estimated based
on the residual amount of biotinylated liposomes
bound to streptavidin which was converted to lipo-
somal PEG-lipid content using a standard curve (see
Results) with the following assumptions: (1) PEG-
lipid is transferred only into the outer membrane of
acceptor liposomes; (2) reduction in biotinylated
liposome binding to streptavidin is attributed to
PEG-lipids in the outer lea£et; (3) PEG-lipids are
symmetrically distributed on the inner and outer leaf-
let of liposomes if PEG-lipids were incorporated in
the initial step of liposome making. With these as-
sumptions, reductions in biotinylated liposome bind-
ing obtained in Fig. 1B were attributed to 50% of the
total PEG-lipid content. This was considered when
extrapolating PEG-lipid content in acceptor lipo-
somes after transfer from donor liposomes. Thus,
the amount of PEG-lipid transferred to biotinylated
acceptor liposome was determined by extrapolating,
based on the level of target binding after transfer and
using Fig. 1B, the liposomal PEG-lipid content
which was then divided by two. Data points pre-
sented are averages between two individual measure-
ments in each experiment with less than 5% standard
deviation.
2.5. PEG-lipid transfer from micelles
PEG-lipid transfer from micelles was done using
DSPE-PEG2000. PEG-lipid micelles were prepared by
dissolving 4 Wmoles of DSPE-PEG2000 in chloroform
with trace amount of 3H-DSPE-PEG2000. After the
lipid mixture was dried under N2 gas and vacuum for
at least 3 h, micelles were formed by adding HBS to
the dried lipid to make a 5 mM solution. In the
transfer experiment, 500 nmoles of biotinylated ac-
ceptor liposomes (with 14C-CHE as liposome label)
were incubated with the indicated amount of PEG-
lipid micelles under conditions speci¢ed for each ex-
periment. After PEG-lipid transfer, liposome binding
to target was assessed using the binding assay de-
scribed above. Transfer of micellar PEG-lipids into
liposomes was also monitored by following the elu-
tion of the PEG-lipid label in a size exclusion col-
umn. 3H-DSPE-PEG micelles were incubated with
non-radiolabeled biotinylated acceptor liposomes
under the conditions speci¢ed in the experiment. Mi-
celles and liposomes were then separated by size ex-
clusion chromatography using a Biogel A15m (100^
200 mesh) column (1.5U42 cm) with a £ow rate of
0.5 ml/min. The amount of 3H radioactivity in the
liposomal peak would indicate the amount of DSPE-
PEG transferred to acceptor liposomes. Total amount
of phospholipid in the liposomal fractions was deter-
mined by organic phosphate measurement [25].
2.6. PEG-lipid exchange in vivo
RAG-2 mice were injected i.v. with DSPC/Chol/
Bx-DSPE liposomes (3 Wmoles/200 Wl/mouse) con-
taining 5 mol% of either C14-Cer-PEG2000, DMPE-
PEG2000, DOPE-PEG2000 or DSPE-PEG2000. At 16 h
after injection, the mice were euthanized and the
plasma was collected. Since the presence of plasma
did not a¡ect the binding of Bx-liposomes to SA
magnetic particles (data not shown), liposome bind-
ing to target can be assessed directly using the plas-
ma samples collected. The plasma was pooled from
three mice in each treatment group and then diluted
accordingly using untreated control mice plasma to
obtain the same lipid concentration for all groups.
One hundred microliters of plasma (containing 42.2
nmoles of lipid) was incubated with 100 Wl of SA
magnetic particles for 2 h. Liposomes bound to SA
magnetic particles were then recovered using a mag-
netic separator and the amount of liposome bound
was determined as described above. Recovery of
liposome binding to streptavidin was used as an in-
direct measure of PEG-lipid released from liposomes.
Alternatively, 3H-labeled PEG-lipids were used to
monitor the retention of PEG-lipid in liposomes.
Balb/c mice were injected i.v. with DSPC/Chol lipo-
somes (3.3 Wmoles/mouse) containing 5 mol% of ei-
ther DSPE-PEG2000, DPPE-PEG2000 or DMPE-
PEG2000 with trace amounts of the respective 3H-
PEG-lipid. 14C-CHE was incorporated in these lipo-
somes as a liposome label. Circulating levels of both
3H-PEG-lipid and 14C-CHE were determined in
blood samples collected at 1, 4, and 24 h after lipo-
some injection.
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3. Results
3.1. PEG-lipid-mediated reductions in biotinylated
liposome binding to streptavidin iron oxide
particles
It is well established that incorporation of PEG-
modi¢ed lipids into liposomes which contain bio-
tinylated lipids can interfere with streptavidin bind-
ing [12,13,26]. In these studies, biotinylated lipo-
somes binding to streptavidin immobilized on
microtiter plates was much reduced when PEG-lipids
were incorporated into liposomes. For this reason,
we proposed that PEG-modi¢ed lipid exchange as-
says could be developed on the basis of PEG-lipid-
mediated reductions in the interactions between bio-
tinylated liposomes and streptavidin immobilized on
magnetic particles. The e¡ect of PEG-lipid content
on the inhibition of biotin-mediated binding of lipo-
somes to streptavidin immobilized on magnetic par-
ticles was measured using DOPC/Chol liposomes
containing 0.1 mol% Bx-DSPE and DMPE-PEG2000
at a concentration ranging from 0 to 5 mol%. The
results (shown in Fig. 1) indicate that the amount of
biotinylated liposomes bound to SA magnetic par-
ticles decreased as the PEG grafting density in-
creased. Instead of a proportional decrease in bind-
ing as a function of PEG-lipid content, a biphasic
decrease in liposome binding was observed. Fig. 1A
was determined under conditions where 500 nmoles
of liposomal lipid were incubated with 100 Wl of
streptavidin SA magnetic particles. When PEG-lipids
were not present, 40 nmoles of liposomes were bound
to the magnetic particles after incubation for 20 min
at which time binding had reached equilibrium. Since
the binding e⁄ciency was only 8% under these con-
ditions, we repeated the assay using lower liposome
concentrations in an e¡ort to demonstrate improved
binding e⁄ciency. When 100 nmoles of biotinylated
liposomes were incubated with the SA magnetic par-
ticles, 25 nmoles bound, as shown in Fig. 1B, and
this was equivalent to approx. 25% of the added
liposomal lipid. Whether using 100 nmoles or 500
nmoles of liposomes, the PEG-lipid-dependent inhi-
bition of binding was comparable (Fig. 1A,B). Inclu-
sion of 0.5 mol% DMPE-PEG2000 caused a 30 and
33% reduction in binding to streptavidin, respec-
tively. However, doubling the PEG-lipid content to
1 mol% only caused a further 8^10% decrease in
binding. When a PEG-lipid content of 5 mol% was
used, there was a 90% reduction in biotinylated lipo-
somes bound to SA magnetic particles, suggesting
e⁄cient steric stabilization of the liposome surface
can be achieved at this PEG grafting density, a result
that is similar to previous ¢ndings [27].
Fig. 1. Biotinylated liposome binding to streptavidin immobi-
lized on superparamagnetic particles (SA magnetic particles) as
a function of liposomal PEG-lipid content. DOPC/Chol lipo-
somes containing 0.1% biotin-X-DSPE and 0^5% DMPE-
PEG2000 were prepared as described in Section 2. Liposomes
bound to SA magnetic particles were measured using either 500
nmoles (A) or 100 nmoles of liposomes (B) which were incu-
bated at room temperature with SA magnetic particles as de-
scribed in Section 2. The data represents averaged results
þ S.D. obtained from 2^4 liposome preparations.
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3.2. Assessing PEG-lipid transfer from donor
liposomes to biotin-labeled acceptor liposomes
A previous study using a £uorescence resonance
energy transfer-based assay demonstrated that
PEG-modi¢ed lipids can transfer from one liposome
population (donor) to another liposome population
(acceptor) [4]. The rate of transfer is dependent on
the ratio of donor to acceptor liposomes as well as
other parameters including the size of the PEG moi-
ety, the acyl chain composition of the PEG-modi¢ed
lipid as well as incubation conditions. The transfer
assay developed in this study relies on the inhibition
of biotinylated liposomes binding to SA magnetic
particles. Therefore, it was important to determine
whether the presence of donor (DSPC/Chol) lipo-
somes changed the binding attributes of these lipo-
somes. As shown in Fig. 2, at all acceptor to donor
liposome ratios tested there was little e¡ect on the
amount of biotinylated (acceptor) liposomes bound
to SA magnetic particles. Since the data suggests that
an acceptor to donor liposome ratio of 1:10 (mol/
mol) can cause a 10% reduction in binding, subse-
quent experiments studying the transfer of PEG-
modi¢ed lipids were completed using an acceptor
to donor ratio of 1:4.
To measure PEG-lipid transfer from DSPC/Chol
liposomes to biotinylated DOPC/Chol liposomes, re-
ductions in biotinylated liposome binding to SA
magnetic particles were measured following incuba-
tion of these acceptor liposomes with donor lipo-
somes containing 5 mol% of either DMPE-PEG2000,
DPPE-PEG2000, or DSPE-PEG2000. PEG-lipid trans-
fer was measured at 4‡C and 37‡C as shown in Fig.
3. The data presented in Fig. 3A shows the amount
of biotinylated liposomes bound to SA magnetic par-
ticles after incubation with the donor liposomes for
the indicated time periods. Fig. 3B represents the
calculated amount (nmoles) of PEG-lipid transferred
to acceptor liposomes, a value determined from the
binding data in Fig. 3A and the inhibition curves
shown in Fig. 1B for data conversion. The results
demonstrate that when the acceptor liposomes were
incubated with donor liposomes containing DMPE-
PEG2000 for 30 min, there was a 53% and 86% re-
duction in acceptor liposome binding to SA magnetic
particles when the incubation temperature was 4‡C
and 37‡C, respectively. The amount of PEG-lipid in
the biotinylated acceptor liposomes was calculated
using the assumption that reductions in binding
were due solely to PEG-lipid transfer to the liposo-
me’s outer lea£et. It was estimated that 2.2 nmoles of
PEG-lipid (22% of total available PEG-lipid) was
transferred to the acceptor liposomes within 30 min
or less at 37‡C. At 4‡C, maximum transfer was ob-
served at the 2 h time point, but the amount of trans-
fer (1.6 nmoles of DMPE-PEG2000) was less than
that observed at 37‡C. The half-times of transfer
for DMPE-PEG2000 at 4‡C and 37‡C, as determined
by this assay, were less than 30 and 15 min, respec-
tively.
The transfer of DPPE-PEG2000 and DSPE-
PEG2000 was less e⁄cient than that of DMPE-
PEG2000, consistent with reports suggesting that the
transfer of PEG-lipids is dependent, in part, on the
acyl chain length of the chemically modi¢ed phos-
phatidylethanolamine used. Transfer of DPPE-
PEG2000 was not detectable at 4‡C (Fig. 3B); how-
Fig. 2. E¡ect of DSPC/Chol liposomes on the binding of bio-
tinylated liposomes to SA magnetic particles. The binding of
biotinylated liposomes to streptavidin can be interfered by the
presence of donor liposomes. DOPC/Chol/Bx-DSPE
(49.9:45:0.1) liposomes (100 nmoles) were incubated with
DSPC/Chol (55:45) liposomes at the indicated acceptor to do-
nor liposome ratios for 24 h at 37‡C. After the incubation, SA
magnetic particles (100 Wl) were added to the liposome mixture
to measure the binding of biotinylated liposomes as described
in Section 2. Data presented are averages between two individu-
al measurements in each experiment with less than 5% standard
deviation.
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ever, at 37‡C the transfer of DPPE-PEG2000 was sig-
ni¢cant as judged by an 80% reduction in acceptor
liposome binding to the SA magnetic particles (Fig.
3A). The transfer of DSPE-PEG2000, on the other
hand, could not be enhanced by increasing the tem-
perature to 37‡C. As shown in Fig. 3B, DSPE-PEG-
lipid transfer was negligible at both 4‡C and 37‡C
(6 0.08 nmoles of PEG-lipid). It should be noted,
however, that there was a consistent 10^20% reduc-
tion in the amount of acceptor liposome binding to
SA magnetic particles observed at the ¢rst time point
following the addition of donor liposomes containing
DSPE-PEG2000. Because this assay is sensitive to
even very small amounts of PEG-lipids, this reduc-
tion in liposome binding, when converted to amount
of PEG-lipid transferred, represents only 0.8% of to-
tal available DSPE-PEG2000.
The amount of DMPE-PEG2000 transferred to ac-
Fig. 3. Inhibition of biotinylated liposome binding to SA magnetic particles mediated by the transfer of PEG-lipids into liposomes.
(A) Inhibition of biotinylated liposome binding to streptavidin as a function of incubation time with donor liposomes containing
DMPE-PEG2000 (F), DPPE-PEG2000 (b), or DSPE-PEG2000 (R). To measure intervesicle PEG-lipid transfer, 100 nmoles of acceptor
liposomes containing DOPC/Chol/Bx-DSPE (54.9:45:0.1) were incubated at either 4‡C (top) or 37‡C (bottom) with donor DSPC/Chol
(50:45) liposomes (400 nmoles) containing 5 mol% of the indicated PEG-lipid. After incubation for the indicated time period, SA
magnetic particles were added to the liposome mixture to measure PEG-lipid-mediated inhibition of biotinylated acceptor liposome
binding to streptavidin as described in Section 2. (B) PEG-lipid content in acceptor liposomes estimated based on the amount of lipo-
somes bound to SA magnetic particles at the end of incubation with donor liposomes. Reduction in biotinylated liposome binding to
streptavidin was converted to liposomal PEG-lipid content using Fig. 1B as described in Section 2. The transfer of PEG-lipid at 4‡C
and 37‡C is presented in the top and bottom panel respectively.
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ceptor liposomes was also measured at equilibrium
as a function of acceptor to donor ratio and the
results, plotted as the calculated amount of PEG-lip-
id transfer, are shown in Fig. 4. With increasing
quantities of donor liposomes (up to 1:4 ratio),
more PEG-lipid was transferred to acceptor lipo-
somes. At an acceptor to donor liposome ratio of
1:1, 1:2, and 1:4, the PEG-lipid content in the ac-
ceptor liposomes at equilibrium was determined to
be 1.06, 1.6, and 2.2 nmoles, respectively. These lev-
els of DMPE-PEG2000 were comparable to the
amount predicted on the basis of three assumptions:
(i) the donor liposomes have 50% of the PEG-modi-
¢ed lipid in the outer lea£et and 50% retained in the
inner lea£et of the liposome bilayer, (ii) only the
DMPE-PEG2000 within the outer lea£et are available
for transfer, and (iii) there is equal distribution of
DMPE-PEG2000 among donor and acceptor lipo-
somes when the transfer has reached equilibrium.
On the basis of these assumptions, there should be
1.25, 1.65, and 2.0 nmoles of DMPE-PEG2000 trans-
ferred to the acceptors when the donor to acceptor
liposome ratios are 1:1, 1:2, and 1:4, respectively. As
shown in Fig. 4, the measured and theoretical values
are comparable.
3.3. Transfer of PEG-modi¢ed lipids from micelles
As shown in Fig. 3A there was a signi¢cant, 20%,
reduction in the amount of acceptor liposome bind-
ing to SA magnetic particles observed even following
addition of donor liposomes prepared with DSPE-
PEG2000. This inhibition could be due to the presence
of low levels of PEG-lipid that did not incorporate
into the liposomes during their preparation. Since it
has been shown by others that PEG-modi¢ed lipids
which do not incorporate into the liposomal mem-
brane will form micelles [28], we investigated the
possibility that the reduction in biotinylated lipo-
some binding to SA magnetic particles was due, in
part, to the presence of PEG-lipid micelles. DSPE-
PEG2000 micelles were prepared as described in Sec-
tion 2 and then incubated with 500 nmoles of bio-
tinylated acceptor liposomes. Subsequently, liposome
binding to SA magnetic particles was measured. Fig.
5A shows the amount of biotinylated liposome
bound to SA magnetic particles as a function of
the amount of DSPE-PEG2000 added, as micelles,
just before the binding assay. Following a 20 min
incubation with SA magnetic particles at room tem-
perature, there was less than a 5% reduction in bio-
tinylated liposome binding observed even in the pres-
ence of 30 nmoles of added DSPE-PEG2000 (Fig.
5A). When the acceptor liposomes were incubated
for 3 h with DSPE-PEG2000 micelles prior to binding
with SA magnetic particles, there was a concentra-
tion-dependent reduction in binding. Similar to the
results obtained with pre-formed PEGylated lipo-
somes (Fig. 1), the inhibition of binding appeared
biphasic. When the amount of added DSPE-
PEG2000 was increased from 0 to 2 nmoles, there
was a 35% reduction in liposome binding to strept-
avidin. However, when DSPE-PEG2000 was increased
from 2 to 25 nmoles (more than 10-fold increase),
liposome binding to streptavidin was reduced further
by only 36%. The results suggest that the added
DSPE-PEG2000 was transferred into the lipid bilayer
of biotinylated liposomes following incubation, con-
sistent with previous studies demonstrating the trans-
fer of PEG-lipids from micelles onto liposomes [29^
31].
To con¢rm that the inhibition in binding mediated
by PEG-lipid micelles is due to the insertion of
DSPE-PEG2000 into pre-formed liposomes, DSPE-
Fig. 4. PEG-lipid transfer as a function of donor liposome con-
centration. Biotinylated acceptor liposomes (100 nmoles) were
incubated at 37‡C with donor liposomes containing 5 mol% of
DMPE-PEG2000 at the indicated ratios to allow PEG-lipid
transfer. When the transfer had reached equilibrium after 2 h,
the amount of PEG-lipid present on acceptor liposomes at equi-
librium was determined by measuring liposome bound to SA
magnetic particles as described for Fig. 3.
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PEG2000 micelles with trace amounts of 3H-DSPE-
PEG2000 were ¢rst incubated with acceptor liposomes
and subsequently fractionated on a size exclusion
column to separate micellar DSPE-PEG- and lipo-
somal PEG-lipid. Using previously published condi-
tions [7], 3H-labeled DSPE-PEG2000 micelles can be
separated from 14C-labeled biotinylated liposomes by
size chromatography on a Biogel A15m column. As
shown in Fig. 6, when 3H-labeled DSPE-PEG mi-
celles (250 nmoles) were added to acceptor liposomes
(5 Wmoles) and then immediately chromatographed,
the majority (s 98%) of the PEG-lipid eluted in the
micellar peak (Fig. 6B). However, if the DSPE-PEG
micelles were incubated for 24 h with acceptor lipo-
somes before column separation, 100% of the 3H-
labeled DSPE-PEG-lipid was recovered in the lipo-
somal fractions indicating complete transfer of the
PEG-lipid into the membrane bilayer of acceptor
liposomes (Fig. 6C). When the amount of DSPE-
PEG2000 micelles used was increased to 750 nmoles
(15% of the total liposomal lipid), it was found that
DSPE-PEG2000 was recovered in both the liposomal
peak and the micellar peak, suggesting that the
amount of DSPE-PEG2000 transfer into liposomes
was saturable. By measuring the total amount of
phosphate in the liposomal peak, it was estimated
that 7 mol% of PEG-lipid was incorporated into
liposomes, presumably in the outer lea£et of the lipo-
somal membrane.
3.4. PEG-lipid exchange in vivo
Our in vitro experiments demonstrate that in the
presence of acceptor liposomes PEG-lipid transfer
can be measured using a functional assay that relies
on the binding of 0.1 Wm liposomes to 1 Wm magnetic
particles. These experiments were conducted under
conditions where an acceptor membrane was present
in excess; however, these conditions can be viewed as
inadequate when considering the membrane and
lipoprotein pools that exist in vivo. To assess the
transfer of PEG-lipids in vivo, an assay based on
similar principles of biotin-mediated binding of lipo-
somes to SA magnetic particles was used. DSPC/
Chol/Bx-DSPE liposomes with and without PEG-lip-
ids were injected into mice and then recovered from
plasma 16 h later. Recovered liposomes were incu-
bated with SA magnetic particles to determine the
binding attributes of these liposomes which in turn
are dependent on exposure of biotin due to the loss
of PEG-lipids. Recovery of target binding, which was
used as an indirect measure of PEG-lipid loss, is ex-
pressed as a ratio of the binding level before and
after injection for each of the liposome formulations
studied. A binding ratio of 1 would indicate no
change in target binding after circulation in vivo.
As expected, liposomes without PEG-lipids had a
reduction in binding to SA particles, likely a result
of serum protein binding to the liposome surface,
making biotin less accessible for binding to streptav-
idin. Similarly for liposomes containing DSPE-
PEG2000, there was a reduction rather than an in-
Fig. 5. E¡ect of micellar PEG-lipid on biotinylated liposome
binding to SA magnetic particles as a function of the amount
of added DSPE-PEG2000. Binding to SA magnetic particles was
measured using 500 nmoles of biotinylated liposomes immedi-
ately after adding DSPE-PEG2000 micelles (A) or after incuba-
tion for 3 h at 37‡C (B) with the indicated amounts of PEG-
lipids.
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crease in target binding after injection into mice. This
¢nding is consistent with our in vitro data indicating
that DSPE-PEG2000 is retained well in the liposomal
membrane. For all other formulations, a binding ra-
tio of greater than 1 was obtained, indicating recov-
ery of binding after circulation in vivo. Changing the
acyl chain composition, either by adding double
bonds (e.g. DOPE-PEG2000), or changing the acyl
chain length, could in£uence the exchangeability of
the PEG-lipid as re£ected by the di¡erent binding
ratios obtained (Fig. 7A). Liposomes made with
DOPE-PEG2000 had a binding ratio of 3.7, corre-
sponding to a 41% recovery in binding when com-
pared to that observed for non-PEGylated formula-
tions after injection into mice. Decreasing the acyl
chain length to C14 caused an increase in the binding
ratio to 8 and 11 for C14-Cer-PEG2000 and DMPE-
PEG2000, respectively. When compared with non-PEG-
Fig. 6. Time-dependent transfer of PEG-lipids from micelles to liposomes. Transfer of DSPE-PEG2000 from micelles was followed us-
ing trace amounts of 3H-labeled PEG-lipid which was incorporated into PEG-lipid micelles. (A) Separation of liposomes from micelles
by size exclusion chromatography. 3H-Labeled DSPE-PEG2000 micelles and biotinylated liposomes containing 14C-CHE (used as a
liposome label) were loaded separately onto a Biogel A15m (100^200 mesh) column (1.5U42 cm) and then chromatographed at a
£ow rate of 0.5 ml/min. (B) Elution pro¢le of 3H-labeled DSPE-PEG2000 which was chromatographed immediately after mixing the
micelles (250 nmoles) with non-radiolabeled biotinylated acceptor liposomes (5 Wmoles). (C) Elution pro¢le of 3H-labeled DSPE-
PEG2000 which was chromatographed after mixing the micelles (250 nmoles) with biotinylated liposomes (5 Wmoles) and incubated at
37‡C for 24 h. (D) Elution pro¢le of 3H-labeled DSPE-PEG2000 which was chromatographed after mixing excess amounts of micelles
(750 nmoles) with biotinylated liposomes (5 Wmoles) and incubated at 37‡C for 24 h.
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ylated liposomes recovered from mice, these lipo-
somes have recovered 72 and 63% of their biotin
binding capacity, respectively.
To con¢rm that recovery in target binding was due
to the loss of PEG-lipids, we conducted an in vivo
experiment using 3H-PEG-lipids and 14C-CHE to
monitor circulating levels of PEG-lipid and lipo-
somes in vivo, respectively. Mice were injected (i.v.)
with liposomes containing 5% of either DSPE-
PEG2000, DPPE-PEG2000, or DMPE-PEG2000. The
relative ratios of PEG-lipid to liposomal lipid were
measured over a 24 h time course following i.v. ad-
ministration of the liposome (Fig. 7B). Con¢rming
our in vitro and in vivo data (Fig. 7A), there was
no measurable level of DSPE-PEG2000 loss from lipo-
somes even when the liposomes were recovered from
the plasma compartment 24 h after i.v. injection. In
contrast, over 40% of the liposome-associated
DMPE-PEG2000 was lost by the ¢rst time point mea-
sured (1 h). The loss of DPPE-PEG2000 in vivo was
more gradual, with 10 and 25% loss of this lipid
observed from liposomes in the plasma compartment
isolated at 4 and 24 h after injection, respectively.
4. Discussion
The method described here to evaluate PEG-modi-
¢ed lipid transfer was based on PEG-lipid-mediated
reductions in biotinylated liposome binding to strept-
avidin magnetic particles. This model was also devel-
oped in consideration of our goal to develop targeted
liposome preparations in which the targeting ligand
used is small enough to be shielded in a controlled
manner by surface-associated PEG polymers. It was
demonstrated that the inclusion of PEG-lipid caused
a concentration-dependent decrease in biotinylated
liposome binding to the SA magnetic particles. How-
ever, the decrease was not proportional to the in-
crease in liposomal PEG content. At low PEG graft-
ing densities, there was an abrupt reduction in
streptavidin binding while the decrease was more
gradual at higher PEG-lipid concentrations. PEG-
mediated inhibition of non-speci¢c protein binding
to surfaces [32] and avidin binding to biotin mole-
cules conjugated to liposomal lipids [27] has been
documented previously. However, the results pre-
sented here suggest that even at low PEG concentra-
Fig. 7. PEG-lipid exchange in vivo. (A) PEG-lipid exchange as
represented by recovery of target binding after circulation in
vivo. Mice were injected with DSPC/Chol/Bx-DSPE liposomes
with or without the indicated PEG-lipids (5 mol%). Liposomes
were recovered from plasma after 16 h to measure binding to
SA magnetic particles as described in Section 2. Recovery in
binding is expressed as a ratio of the level of target binding be-
fore and after injection into mice. Data shown represent the
mean of two individual measurements in the binding assay us-
ing plasma pooled from three mice for each liposome formula-
tion. (B) PEG-lipid exchange as measured using radiolabeled
PEG-lipids. DSPC/Chol liposomes containing 5 mol% of either
DSPE-PEG2000, DPPE-PEG2000, or DMPE-PEG2000 with trace
amounts of the respective 3H-PEG-lipid were injected into mice
to monitor the elimination of both 3H-PEG-lipid and 14C-CHE
which was used as a liposome label. A ratio of the % recovery
of 3H-PEG-lipid/14C-CHE was obtained at 1, 4, and 24 h after
liposome injection as described in Section 2. Data shown repre-
sent averaged results obtained from four mice þ S.D.
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tions, much lower than those required to in£uence
protein binding, there is signi¢cant inhibition of sur-
face^surface binding reactions. In the model devel-
oped here, PEG-modi¢ed lipids incorporated at con-
centrations less than 0.1 mol% can signi¢cantly
reduce the binding of 0.1 Wm liposomes to 1 Wm
particles. This discussion is focused on how PEG
acts to limit the interactions between two particles
as well as the role that PEG-lipid transfer can have
in the design of targeted liposomal formulations.
It was originally proposed by de Gennes [33] that
surface-grafted polymers exist in two conformations
depending on the grafting density. When the grafting
density is low, where the Flory radius (Rf ) of the
polymer is smaller than the distance between grafting
points on the surface (D), the polymer is envisioned
to be in the ‘mushroom’ conformation. When the
grafting density is high, where Rf sD, the polymer
is in the ‘brush’ con¢guration [33]. Thus, the surface
area covered by the polymer is predicted to be di¡er-
ent for the two regimes [33]. Du et al. [32] reported
that protein adsorption decreases steeply at PEG5000
concentrations below 1 mol%, very close to 0.7 mol%
at which the 5000 average molecular weight polymer
is predicted to undergo transition to the brush con-
formation, supporting that the di¡erent e¡ectiveness
of PEG on surface shielding is due to changes in
polymer conformation. However, for shorter chain
polymers such as PEG2000, the transition between
mushroom and brush conformation is not as distinct.
Based on the prediction of Needham et al. [34], the
transition occurs at 4 mol% for PEG2000, whereas
Rex et al. reported that PEG2000 would be in the
mushroom con¢guration at concentrations as high
as 9 mol% [35]. Regardless, it is likely that the mush-
room conformation was obtained with the PEG-lipid
concentrations used in this study and we still ob-
served a pattern of non-linear surface shielding sim-
ilar to the ¢nding of others using PEG750 [27]. Thus,
the distinctive shielding properties obtained with dif-
ferent grafting densities of shorter PEG cannot be
simply explained by the two di¡erent conformations
of the polymer.
In contrast to most studies which measure the
binding of free molecules to liposome surface
[27,32,36], our PEG shielding assay is based on lipo-
some binding to a target molecule on a larger sur-
face, mimicking the situation of a target cell. It was
surprising to note that there was a signi¢cant reduc-
tion in target binding when the content of PEG-
modi¢ed lipid was less than 0.1%. This indicates
that even low levels of grafted PEGs are su⁄cient
to interfere with particle^particle binding when mea-
suring the interactions between liposomes with target
molecules on a larger surface. This observation is
consistent with previous studies that indicate PEG-
lipids inhibited binding between antibody-targeted
liposomes and their target cell population [37,38].
In contrast, it was noted that the binding of free
biotin to avidin conjugated to liposomal surface
was una¡ected at PEG-lipid concentrations as high
as 2% [36]. Thus, it appears that PEG-lipids can
prevent speci¢c interaction with molecules ¢xed on
a larger surface better than with molecules free in
solution. The di¡erential e¡ect of PEG in preventing
adsorption of free vs. bound target molecules may be
explained by the size of the target molecule, which in
turn determines its mobility. As noted by Needham
et al., the hydrated PEG layer provides a barrier that
acts like a molecular sieve when measuring penetra-
tion and binding of molecules to liposomes [34].
Larger polymers such as PEG2000 and PEG5000 can
restrict larger molecules (as in the case of molecules
bound to a larger surface) while they are less e¡ective
in preventing penetration of smaller molecules. This
result has implications with respect to our goal of
designing ligand-targeted liposomes that rely on the
use of PEG-lipid shielding of the surface-associated
targeting ligand. Our laboratory believes that it is
important to develop targeted liposomes with time-
controlled release of PEG-lipids to protect liposomes
while in the circulation, and to subsequently expose
the shielded ligand for targeting when exiting the
circulation.
Using the relationship obtained between the PEG
content of biotinylated liposome and liposome bind-
ing to streptavidin immobilized on magnetic par-
ticles, we measured PEG-mediated inhibition of bio-
tin liposome binding as a functional assay to
determine PEG-lipid transfer. Consistent with other
reports, we found that the transfer of PEG-lipids
from DSPC/Chol donor liposomes was dependent
on temperature and the acyl chain length of the lipid
anchor [4,6,23]. Using this method, we were able to
quantitate PEG-lipid transfer with reasonable accu-
racy. Our experimental results compared well with
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theoretical predictions determined on the basis of
several assumptions. These assumptions include the
equal distribution of PEG-lipids in the outer and
inner lea£ets of the ‘donor’ liposomes which is sup-
ported by the prediction that the curvature of the
inner lea£et of a bilayer of a 100 nm liposome would
not be constrained su⁄ciently to a¡ect the bilayer
distribution of lipids with covalently linked
PEG2000. It was also assumed that only PEG-lipids
in the outer lea£et would be transferred and that at
equilibrium the concentration of PEG-lipids in the
outer lea£et of the acceptor and donor liposomes
would be equal. An equally important assumption
made in the development of this model concerned
the mechanism of PEG-lipid transfer. Based on the
conclusions of Silvius and Zuckermann [6] as well as
studies demonstrating PEG-mediated inhibition of
liposome^liposome interactions [36], it is believed
that PEG-lipid transfer occurred by monomer di¡u-
sion or via a micellar intermediate. It is demon-
strated that DSPE-PEG2000 presented in micelles
can facilitate DSPE-PEG2000 transfer to the ‘accep-
tor’ liposomes. We believe, however, that inter-lipo-
some PEG-lipid transfer is not due to excess PEG-
lipid in micellar form co-existing with donor lipo-
somes. This interpretation is based, in part, on data
suggesting that a maximum of 7 mol% PEG-lipids
can be incorporated asymmetrically into pre-formed
liposomes. Assuming the outer and inner lea£ets of
liposomes have an equivalent capacity for PEG-lip-
ids, a total of approx. 14 mol% of DSPE-PEG2000
can be incorporated into liposomes before excess
PEG-lipids form micelles.
The ¢nding that DSPE-PEG2000 from micelles, but
not liposomes, is readily incorporated into pre-
formed liposomes indicates that desorption of phos-
pholipid is the rate-limiting step in the transfer pro-
cess, in agreement with the mechanism proposed by
Jones and Thompson [22]. Many factors which a¡ect
the rate of phospholipid desorption have been iden-
ti¢ed. These include the degree of unsaturation of the
acyl chains of the lipid anchor [23], donor liposome
lipid environment and size [22,39], temperature and
ionic strength of bu¡er [22], and acyl chain length of
the lipid anchor which seems to have the most prom-
inent e¡ect on the rate of transfer [23].
The time course of PEG-lipid transfer has very
important implications in designing liposomes for
therapeutic and diagnostic purposes. Our in vitro
data indicated that PEG-lipids with short acyl chains
(C14:0) exhibit the fastest rate of transfer, which
occurs on a time scale of minutes at 37‡C. This ¢nd-
ing is well correlated with our in vivo results which
demonstrate that liposomes made with DMPE-
PEG2000 lost most of the PEG-lipid within 1 h. We
believe that a slower rate of PEG-lipid removal is
required to protect liposomes in the circulation for
a su⁄cient period of time before leaving this com-
partment. The rapid removal of DMPE-PEG2000
from fusogenic vesicles has been shown to result in
their rapid elimination from the circulation and a
reduction in stability of the drug-loaded formulations
prepared using this lipid [5]. DPPE-PEG2000 or
DOPE-PEG2000, on the other hand, exhibit slower
rates of transfer, where lipid loss occurs over a
time scale of hours according to our in vitro and in
vivo data. Knowing that liposome accumulation in
tumors reaches its maximum between 16 and 24 h
[40,41], it is predicted that these PEG-modi¢ed lipids
will provide the ideal choice for time-controlled ex-
posure of liposomal ligand for targeting. In conclu-
sion, our data indicate that PEG-lipid transfer can
lead to recovery of liposome binding attributes and
that this recovery of binding is dependent on the
attributes of the PEG-modi¢ed lipid used. Further
characterization of this approach, where a targeting
ligand is shielded for a controlled time period follow-
ing intravenous administration, is currently under-
way.
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